𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines

✍ Scribed by Aniruddha Choudhury; Jehad Charo; Sunil K. Parapuram; Richard C. Hunt; D. Margaret Hunt; Barbara Seliger; Rolf Kiessling


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
430 KB
Volume
108
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Silencing of a specific mRNA using double stranded RNA oligonucleotides represents one of the newest technologies for suppressing a specific gene product. Small interfering RNA (siRNA) are 21 nucleotides long, double stranded RNA fragments that are identical in sequence to the target mRNA. We designed 3 such siRNA against the Her2/neu (HER2) gene. The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers. Introduction of the siRNA into HER2 positive tumor lines in vitro greatly reduced the cell surface expression of the HER2 protein. Concurrently, a range of effects on cell physiology, such as growth inhibition or apoptosis, was observed. The expression of HLA class I was observed to be upregulated when HER2 was silenced with siRNA. Treatment of SKBr3 and MCF7/HER2 tumor cell lines with the HER2 siRNA resulted in growth arrest of cells in the late G~1~/S‐phase. Our results suggest that siRNA may be an effective method of abrogating the effect of HER2 in tumorigenesis. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Effects of the tyrosine-kinase inhibitor
✍ Frank Hartmann; Eva M. Horak; Cheryl Cho; Ruth Lupu; Joseph B. Bolen; Mary A. St 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 408 KB 👁 2 views

Geldanamycin belongs to the family of benzoquinoid ansamycin tyrosine-kinase inhibitors. We have examined its effects on Her-2/neu kinase activity, protein expression level, and proliferation of Her-2+ malignant cells. In SK-BR-3 breast-cancer cells, short-time treatment with geldanamycin completely